| Similar Articles |
|---|
 |
IEEE Spectrum
October 2011
Joseph M. Smith |
Wireless Health Care Wireless technologies are about to transform health care, and not a moment too soon   |
Pharmaceutical Executive
August 1, 2011
Jennifer Ringler |
The Adherence Fight: A TKO? Why does the match against medicines compliance always seem to end in an easy knockout? |
Pharmaceutical Executive
June 1, 2014
Ben Comer |
Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy. |
Pharmaceutical Executive
August 1, 2008
George Koroneos |
Hard of (Ad)hering Companies have responded to declining profits with a proliferation of patient compliance programs. But where is pharma in this paradigm shift? |
BusinessWeek
April 1, 2010
Kerry Capell |
Remote Health Care: Body Parts Make Phone Calls Facing saturated markets, cellular carriers are jumping into the revolution of mobile technology that identifies and acts on medical problems. |
Pharmaceutical Executive
December 1, 2011
William Looney |
The Medicines Adherence Challenge Keeping skittish patients on their medicines ought to be a strategic priority for Big Pharma, but is it? An expert round table examines how best to make progress and agree on some practical steps for incorporation in the campaign agenda. |
Pharmaceutical Executive
July 1, 2009
Patrick Clinton |
What to Buy In the long run, pharma wants to sell health, not just drugs. |
CIO
April 27, 2009
James Niccolai |
Home Healthcare Devices Help Patients Stay out of the Hospital Remote devices allow patients to monitor their health at home and reduce hospital visits. |
Pharmaceutical Executive
September 1, 2005
Charlene Prounis |
Marketing to Professionals: Doctor-Patient Communication Improving doctor-patient relations can lead to increased patient compliance. |
Pharmaceutical Executive
February 1, 2011
Jennifer Ringler |
Skipping the Needle: Pharm Exec's Brand of the Year Novartis' Gilenya is a step forward in treating Multiple Sclerosis. But generating increased compliance is another story |
Pharmaceutical Executive
June 1, 2013
Clark Herman |
Adherence's New Players: Fresh Support from the Sidelines New stakeholders, innovative technologies, and emergent synergies in government are combining to build fresh momentum behind the old issue of medication adherence. |
The Motley Fool
May 17, 2010
Luke Timmerman |
Vertex Awaits Final Proof that Hepatitis C Drug Works For this drug researcher, the proof is in the telaprevir. |
Pharmaceutical Executive
September 1, 2012
Al Topin |
Doctors' Words No Longer Gospel In the digital age, physicians don't call the shots when it comes to healthcare guidance. Marketers must appeal to multiple sources in seeking ways to garner patient adherence and loyalty. |
Managed Care
May 2007
Rachel M. Renshaw |
Keys to Diabetes Control? Patience, Persistence, and Perseverance Careful attention to a comprehensive treatment plan could forestall or prevent the need to add drugs and costs to a patient's regimen. |
The Motley Fool
March 16, 2011
Brian Orelli |
Different Name, Same Great Results Incyte and Novartis' ruxolitinib passes another clinical trial. |
Pharmaceutical Executive
December 1, 2013
Vansgaard et al. |
Develop Drugs for People, Not Just Bodies A patient-centric approach to drug development delivers the benefits that actually create value |
American Family Physician
September 1, 2006
Gardiner & Dvorkin |
Promoting Medication Adherence in Children The problem of getting children to follow a treatment regimen is widespread and is frustrating for physicians. Having the child participate in devising the plan improves adherence. |
Pharmaceutical Executive
February 1, 2012
Sarah Krug |
Introducing the 'Chief Patient Officer' Now is the time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust. |
Nursing
June 2011
Daniel A. Hussar |
New Drugs 2011: Part 2 In this article, you'll learn about seven recently approved drugs, including: fingolimod hydrochloride, an oral drug indicated to treat patients with relapsing forms of multiple sclerosis. |
Pharmaceutical Executive
May 1, 2009
Maryann Kuzel |
Weathering the Storm Marketers must stress that maintaining good health behaviors is one of the best things people can do to survive a down market. |
The Motley Fool
September 7, 2010
Luke Timmerman |
Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too. |
Nursing
January 2011
Carl A. Kirton |
HIV: The Changing Epidemic Since its emergence in the early 1980s, HIV infection in the United States has evolved from an acute debilitating condition to a chronic, treatable illness. |
BusinessWeek
November 5, 2009
Arlene Weintraub |
Elder Care by Remote A new technology trend called "aging in place" is designed to help seniors stay longer where they're most comfortable -- at home -- rather than having to move into nursing or assisted-living facilities. |
IEEE Spectrum
March 2011
Samuel K. Moore |
Teaching Machines About Madness Software rivals doctors at distinguishing among different kinds of depression and schizophrenia |
Inc.
June 2009
Nicole Marie Richardson |
Innovation: CardioMEMS EndoSure Sensor CardioMEMS creates body sensors that monitor cardiovascular health. |
Pharmaceutical Executive
April 1, 2011 |
Off-Label But On Point? Use of off-label drugs is a balancing act for physicians, and poses even more problems for pharma. The FDA is moving slowly to help. |
Pharmaceutical Executive
January 1, 2012
Elys Roberts & Sarah Phillips |
The Emergence of the Pro-Patient How can pharma embrace and interact with increasingly informed and demanding patients to bring positive outcomes for all? |
Pharmaceutical Executive
March 1, 2013
Al Topin |
Less Selling, More Time What can happen when pharmaceutical reps focus on the physician-patient conversation? |
Managed Care
October 2007
Martin Sipkoff |
Asheville's Legacy: Pharmacy Moves From Dispensing to Clinical Management It is an idea whose time has finally come: Today's clinical pharmacists are involved in virtually all aspects of medical care. |
Fast Company
Sindya N. Bhanoo |
When Wearable Tech Saves Your Life, You Won't Take It Off A small cadre of companies has been furiously working to develop smaller, sleeker, more discreet devices that monitor health and wellness -- in the form of temporary tattoos, band-aids, and ingestible pills. |
The Motley Fool
May 31, 2011
Brian Orelli |
5 Biotechs With Upcoming Clinical Trial Results Investors willing to stay in these stocks a little while could see substantial gains well ahead of FDA approvals. |
Managed Care
September 2006
David Adler |
Pharma Tackles Patient Adherence Drug manufacturers' programs include Web-based reminders, financial incentives, and full-blown disease management |
The Motley Fool
August 9, 2010
Luke Timmerman |
Affymax Lives to Fight Another Day Affymax takes on Amgen with its anemia drug. |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
The Motley Fool
June 6, 2011
Luke Timmerman |
Exelixis Zeroes In on Lead Drug, Sees Activity in the Bones of Prostate Cancer Patients Is Exelixis' risky bet about to pay off? |
Pharmaceutical Executive
January 1, 2007
Nihal Mehta |
Alternative Media: Honey, I Shrunk the Ad Campaign Pharma companies turn to mobile technology to deliver health information and sample coupons direct to consumers' cell phones. |
The Motley Fool
February 28, 2011
Brian Orelli |
Look Out for Big Growth From This Drug Regeneron's ultra-orphan drug Arcalyst takes a step forward toward a wider audience. |
Pharmaceutical Executive
September 1, 2011 |
(Some) Booths Beckon What some pharma companies are doing about the increasing restrictions of face-to-face interaction between industry and prescribing physicians. |
The Motley Fool
April 13, 2011
Brian Orelli |
Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients. |
Pharmaceutical Executive
September 1, 2011
Richard Gliklich |
The Power of Observation Observational studies present a compelling real-world corollary to the classic randomized clinical trial. |
Pharmaceutical Executive
April 1, 2011 |
Winning Beyond the Molecule It can take both a clinical and non-clinical approach to win the differentiation competition. |
Pharmaceutical Executive
April 1, 2012
Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
The Motley Fool
June 28, 2010
Luke Timmerman |
Orexigen Drug Shows Potential as "Two-Fer" Against Obesity and Diabetes Orexigen's latest drug aims at treating both diabetes and obesity. |
Nurse Practitioner
March 2012
Baumann & Dang |
Helping Patients with Chronic Conditions Overcome Barriers to Self-Care Here are approaches nurse practitioners can use to reduce or eliminate barriers to self-care in adults with chronic conditions. |
Chemistry World
July 2010 |
Meeting Mr NICE guy Bibiana Campos-Seijo meets the chief executive of the National Institute for Health and Clinical Excellence, Sir Andrew Dillon |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
Pharmaceutical Executive
July 10, 2014
Ben Comer |
WebMD: The Patient Value Equation For WebMD CEO David Schlanger, connecting patients with physicians through a robust digital platform delivers the winning formula necessary to achieve quality of care, cost savings, and better health outcomes. |
Pharmaceutical Executive
February 1, 2007
Bill Chekan |
Ain't Misbehavin' Missing doses and other medication meddling are often no accident. A new study of patient compliance uncovers methods to the madness. |
Pharmaceutical Executive
June 1, 2013
William Looney |
Recognizing the Best Getting patients to take their medicine on spec and on time is the challenge that never goes away; it's the deadweight baggage accompanying every industry innovation since the arrival of aspirin a century ago. |
The Motley Fool
January 25, 2011
Brian Orelli |
2 Keys to Amgen's Continued Success Prolia and Xgeva have to perform. |
